An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
Wenle Xia(Duke Medical Center), Neil L. Spector(Duke University), Sumin Zhao(Language Science (South Korea)), Julia Wulfkuhle(University of California, San Francisco), Sarah Bacus(Sequella (United States)), William R. Gwin(Duke Medical Center), Rosa I. Gallagher(George Mason University), Xiaoyi Yang(Science Applications International Corporation (United States)), Takuya Osada(Rakuten (Japan)), Qing Cheng(Southern Medical University), Lei-Hua Liu(Duke Medical Center), Emanual Petricoin(George Mason University), H. Kim Lyerly(Duke University)
Cited by 146
Related Papers
Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
|Journal of Clinical Oncology|2005|364
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
|Cancer Cell|2022|335
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
|Cancer Cell|2021|330
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy
|Journal of Immunotherapy|2002|299